| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma C Robert, L Thomas, I Bondarenko, S O'Day, J Weber, C Garbe, C Lebbe, ... New England Journal of Medicine 364 (26), 2517-2526, 2011 | 5580 | 2011 |
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial A Hauschild, JJ Grob, LV Demidov, T Jouary, R Gutzmer, M Millward, ... The Lancet 380 (9839), 358-365, 2012 | 3636 | 2012 |
| Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ... The lancet oncology 16 (4), 375-384, 2015 | 3126 | 2015 |
| Talimogene laherparepvec improves durable response rate in patients with advanced melanoma RHI Andtbacka, HL Kaufman, F Collichio, T Amatruda, N Senzer, ... Journal of clinical oncology 33 (25), 2780-2788, 2015 | 2830 | 2015 |
| Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ... New England Journal of Medicine 380 (12), 1103-1115, 2019 | 2473 | 2019 |
| Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort … A Marabelle, M Fakih, J Lopez, M Shah, R Shapira-Frommer, ... The Lancet Oncology 21 (10), 1353-1365, 2020 | 2035 | 2020 |
| Chromosomal translocation t (15; 17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML A Kakizuka, WH Miller Jr, K Umesono, RP Warrell Jr, SR Frankel, V Murty, ... Cell 66 (4), 663-674, 1991 | 1791 | 1991 |
| Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid) RP Warrell Jr, SR Frankel, WH Miller Jr, DA Scheinberg, LM Itri, ... New England Journal of Medicine 324 (20), 1385-1393, 1991 | 1615 | 1991 |
| Role of the histone deacetylase complex in acute promyelocytic leukaemia RJ Lin, L Nagy, S Inoue, W Shao, WH Miller Jr, RM Evans Nature 391 (6669), 811-814, 1998 | 1436 | 1998 |
| Mechanisms of action of arsenic trioxide WH Miller Jr, HM Schipper, JS Lee, J Singer, S Waxman Cancer research 62 (14), 3893-3903, 2002 | 1319 | 2002 |
| Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): I. As2O3 Exerts Dose-Dependent Dual Effects on APL Cells GQ Chen, XG Shi, W Tang, SM Xiong, J Zhu, X Cai, ZG Han, JH Ni, ... Blood, The Journal of the American Society of Hematology 89 (9), 3345-3353, 1997 | 1015 | 1997 |
| A review of cancer immunotherapy: from the past, to the present, to the future K Esfahani, L Roudaia, N Buhlaiga, SV Del Rincon, N Papneja, WH Miller Current Oncology 27 (s2), 87-97, 2020 | 1006 | 2020 |
| A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein JA Dyck, GG Maul, WH Miller Jr, JD Chen, A Kakizuka, RM Evans Cell 76 (2), 333-343, 1994 | 971 | 1994 |
| Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite … CM Rocha Lima, MR Green, R Rotche, WH Miller Jr, GM Jeffrey, LA Cisar, ... Journal of Clinical Oncology 22 (18), 3776-3783, 2004 | 704 | 2004 |
| Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis SP D’Angelo, J Larkin, JA Sosman, C Lebbé, B Brady, B Neyns, ... Journal of clinical oncology 35 (2), 226-235, 2017 | 624 | 2017 |
| Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies J Baselga, L Norton, H Masui, A Pandiella, K Coplan, WH Miller Jr, ... JNCI: Journal of the National Cancer Institute 85 (16), 1327-1333, 1993 | 558 | 1993 |
| Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label … J Larkin, D Minor, S D'Angelo, B Neyns, M Smylie, WH Miller Jr, ... Journal of clinical oncology 36 (4), 383-390, 2018 | 557 | 2018 |
| Phase I clinical trial of iv ascorbic acid in advanced malignancy LJ Hoffer, M Levine, S Assouline, D Melnychuk, SJ Padayatty, K Rosadiuk, ... Annals of Oncology 19 (11), 1969-1974, 2008 | 522 | 2008 |
| Continuous treatment with all-transretinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients … J Muindi, SR Frankel, WH Miller Jr, A Jakubowski, DA Scheinberg, ... Blood 79 (2), 299-303, 1992 | 515 | 1992 |
| Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial J Rodon, JC Soria, R Berger, WH Miller, E Rubin, A Kugel, A Tsimberidou, ... Nature medicine 25 (5), 751-758, 2019 | 505 | 2019 |
Gerald BatistProfessor,McGill UniversityPatvirtintas el. paštas mcgill.ca
